Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
The Lancet. Haematology|January 28, 2021
Improving prognostication and management of systemic mastocytosisSimona Soverini
Hematology. American Society of Hematology. Education Program|December 9, 2023
Resistance mutations in CML and how we approach themSimona Soverini
The Lancet. Haematology|December 22, 2015
Interferon in CML: back to the past, or towards the future?Simona Soverini, Giovanni Martinelli
Blood|July 26, 2014
Molecular response in CML: where is the bar?Michele Baccarani, Simona Soverini
Seminars in Hematology|July 23, 2009
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemiaElias Jabbour, Simona Soverini
Blood|May 15, 2025
How I Evaluate and Treat Resistance and Relapse in CMLSimona Soverini, Fausto Castagnetti
Journal of Hematology & Oncology|April 25, 2019
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSimona Soverini, Renato Bassan, Thomas Lion
The Lancet. Haematology|May 1, 2019
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?Simona Soverini, Margherita Martelli, Luana Bavaro
Leukemia|August 29, 2019
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript typeMichele Baccarani, Gianantonio Rosti, Simona Soverini
The Lancet. Haematology|November 29, 2016
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemiaSimona Soverini, Michele Baccarani, Giovanni Martinelli
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
The Lancet. Haematology|January 28, 2021
Improving prognostication and management of systemic mastocytosisSimona Soverini
Hematology. American Society of Hematology. Education Program|December 9, 2023
Resistance mutations in CML and how we approach themSimona Soverini
The Lancet. Haematology|December 22, 2015
Interferon in CML: back to the past, or towards the future?Simona Soverini, Giovanni Martinelli
Blood|July 26, 2014
Molecular response in CML: where is the bar?Michele Baccarani, Simona Soverini
Seminars in Hematology|July 23, 2009
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemiaElias Jabbour, Simona Soverini
Blood|May 15, 2025
How I Evaluate and Treat Resistance and Relapse in CMLSimona Soverini, Fausto Castagnetti
Journal of Hematology & Oncology|April 25, 2019
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSimona Soverini, Renato Bassan, Thomas Lion
The Lancet. Haematology|May 1, 2019
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?Simona Soverini, Margherita Martelli, Luana Bavaro
Leukemia|August 29, 2019
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript typeMichele Baccarani, Gianantonio Rosti, Simona Soverini
The Lancet. Haematology|November 29, 2016
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemiaSimona Soverini, Michele Baccarani, Giovanni Martinelli
Pageof 17